EUVIMEDEUVIMED entdecken
Crossref

Impact of the Individualized 4‐Year Physiotherapy on the Musculoskeletal System and Quality of Life of Patients With Severe Hemophilia A With Inhibitors

Maria Podolak-Dawidziak, Janusz Zawilski, Ewa Stefańska-Windyga, Magdalena Górska-Kosicka, Anna Buczma, Ewa Chmielewska, Jolanta Oleksiuk, Joanna Zdziarska iD, Andrzej Mital, Mariola Bober, Justyna Kozińska, Michał Jamrozik und 2 weitere

Haemophilia · 2025

DOI: 10.1111/hae.70094 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, 2025. Verfasst von Maria Podolak-Dawidziak und 13 weiteren Autor:innen. Beteiligte Einrichtung: Wroclaw Medical University, Department and Clinic of Hematology, Cellular Therapies and Internal Medicine, Wrocław, Poland. Hauptthemen laut MEDLINE: Hemophilia A, Quality of Life, Physical Therapy Modalities. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Baxalta GmbH, Takeda Pharmaceutical Company Limited, Takeda Pharmaceutical Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The development of factor VIII inhibitors is a significant complication of hemophilia A, increasing the risk of bleeding and resulting in high morbidity. Recurrent joint bleeds lead to severe arthropathy and a reduced quality of life compared to patients without inhibitors. Although recent therapies have improved outcomes, many patients with longstanding inhibitors already experience irreversible joint damage. Research on rehabilitation in hemophilia, particularly for patients with inhibitors, remains limited.

Aim

This 4‐year study evaluated the impact of individualized physiotherapy on musculoskeletal health and quality of life (QoL) in severe hemophilia A patients with inhibitors.

Methods

Twenty‐five adults (aged 19–69) with severe hemophilia A and inhibitors received personalized home physiotherapy supervised by a specialist, alongside biannual 5‐day rehabilitation camps. Prophylactic activated prothrombin complex concentrate (aPCC) was administered. Joint status was assessed biennially via Hemophilia Joint Health Score (HJHS) and MRI of target joints; QoL was measured using EQ‐5D questionnaires.

Results

No bleeding episodes occurred during prophylaxis. Thirteen patients completed follow‐up. MRI scores stabilized (mean change: +1.3 points; 95% CI: 0.3–2.3), while HJHS improved significantly from 41.1 (95% CI: 32.5–49.7) to 24.9 (95% CI: 16.9–32.7). EQ‐5D scores rose from 54.0 (95% CI: 48.2–59.8) to 86.7 (95% CI: 81.9–91.5), reflecting enhanced mobility, reduced pain and greater independence.

Conclusion

Individualized rehabilitation with aPCC prophylaxis significantly improved joint function (notably pain and mobility) and QoL, despite limited MRI changes due to pre‐existing arthropathy. These results advocate for long‐term, tailored physiotherapy in inhibitor patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AQuality of LifePhysical Therapy ModalitiesHumansAdultMiddle AgedMaleYoung AdultAgedFemaleFactor VIII

Stichwörter der Autor:innen

activated prothrombin complex concentrates (aPCC)factor VIII inhibitorhaemophilia Aindividualized physiotherapy

Substanzen

Factor VIII

Autor:innen und Institutionen

  • Wroclaw Medical University, Department and Clinic of Hematology, Cellular Therapies and Internal Medicine, Wrocław, Poland.
  • Medical Center Interlab, Poznań, Poland.
  • Department of Hemostasis Disorders and Internal Diseases, Institute of Hematology and Transfusion Medicine in Warsaw, Warsaw, Poland.
  • Department of Hematology and Transplantology, Pomeranian Medical University in Szczecin, Szczecin, Poland.
  • Department of Hematology, Internal Diseases and Angiology with a Subdivision of Hematopoietic Cell Transplantation, University Clinical Hospital in Bialystok, Bialystok, Poland.
  • Clinical Department of Hematology and Internal Diseases, University Hospital in Cracow, Kraków, Poland.

ORCID-Profile: Joanna Zdziarska, Monika Biernat

Förderung

  • Baxalta GmbH
  • Takeda Pharmaceutical Company Limited
  • Takeda Pharmaceutical Company

Zitieren

APA

Podolak-Dawidziak, M., Zawilski, J., Stefańska-Windyga, E., Górska-Kosicka, M., Buczma, A., Chmielewska, E., Oleksiuk, J., Zdziarska, J., Mital, A., Bober, M., Kozińska, J., Jamrozik, M., Biernat, M., & Brzozowska, A. (2025). Impact of the Individualized 4‐Year Physiotherapy on the Musculoskeletal System and Quality of Life of Patients With Severe Hemophilia A With Inhibitors. Haemophilia. https://doi.org/10.1111/hae.70094

Vancouver

Podolak-Dawidziak M, Zawilski J, Stefańska-Windyga E, Górska-Kosicka M, Buczma A, Chmielewska E, et al. Impact of the Individualized 4‐Year Physiotherapy on the Musculoskeletal System and Quality of Life of Patients With Severe Hemophilia A With Inhibitors. Haemophilia. 2025. doi:10.1111/hae.70094

BibTeX
@article{PodolakDawidziak2025,
  author = {Podolak-Dawidziak, Maria and Zawilski, Janusz and Stefańska-Windyga, Ewa and Górska-Kosicka, Magdalena and Buczma, Anna and Chmielewska, Ewa and Oleksiuk, Jolanta and Zdziarska, Joanna and Mital, Andrzej and Bober, Mariola and Kozińska, Justyna and Jamrozik, Michał and Biernat, Monika and Brzozowska, Agnieszka},
  title = {Impact of the Individualized 4‐Year Physiotherapy on the Musculoskeletal System and Quality of Life of Patients With Severe Hemophilia A With Inhibitors},
  journal = {Haemophilia},
  year = {2025},
  doi = {10.1111/hae.70094}
}
Kostenlos starten →